Compare PRPL & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRPL | LUNG |
|---|---|---|
| Founded | 2010 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.9M | 72.2M |
| IPO Year | 2015 | 2020 |
| Metric | PRPL | LUNG |
|---|---|---|
| Price | $0.70 | $1.35 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $1.00 | ★ $5.38 |
| AVG Volume (30 Days) | 203.9K | ★ 680.2K |
| Earning Date | 05-05-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.22 | 7.64 |
| EPS | ★ 0.45 | N/A |
| Revenue | ★ $487,877,000.00 | $90,497,000.00 |
| Revenue This Year | N/A | $6.20 |
| Revenue Next Year | $12.69 | $21.61 |
| P/E Ratio | $1.55 | ★ N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $0.56 | $1.31 |
| 52 Week High | $1.26 | $7.97 |
| Indicator | PRPL | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 49.25 | 37.62 |
| Support Level | $0.65 | N/A |
| Resistance Level | $0.74 | $2.01 |
| Average True Range (ATR) | 0.04 | 0.17 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 55.07 | 5.29 |
Purple Innovation Inc is a comfort innovation company. The company designs, manufactures and sells a range of comfort technology offerings, including mattresses, a pillow, cushions, sheets, bed platforms and other products. The Company has one reportable segment that operates an omni-channel distribution which allows the Company to offer a seamless shopping experience to its customers across multiple sales channels. It sells its products through its direct-to-consumer e-commerce channels, retail brick-and-mortar wholesale partners, Purple showrooms, and third-party online retailers.
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.